Mazurek M - Search Results

1

Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.

Mazurek M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Paquette M, Zint K, França LR, Lu S, Bartels DB, Huisman MV, Lip GYH; GLORIA-AF Investigators. Mazurek M, et al. Am Heart J. 2019 Dec;218:123-127. doi: 10.1016/j.ahj.2019.08.012. Am Heart J. 2019. PMID: 31806087

2

Polish and European management strategies in patients with atrial fibrillation. Data from the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot).

Lenarczyk R, Mitręga K, Mazurek M, Janion M, Opolski G, Drożdż J, Streb W, Fuglewicz A, Sokal A, Laroche C, Lip GY, Kalarus Z. Lenarczyk R, et al. Among authors: mazurek m. Pol Arch Med Wewn. 2016;126(3):138-48. doi: 10.20452/pamw.3322. Epub 2016 Mar 22. Pol Arch Med Wewn. 2016. PMID: 27000745 Free article.

3

To occlude or not? Left atrial appendage occlusion for stroke prevention in atrial fibrillation.

Mazurek M, Lip GY. Mazurek M, et al. Heart. 2017 Jan 15;103(2):93-95. doi: 10.1136/heartjnl-2016-310255. Epub 2016 Sep 12. Heart. 2017. PMID: 27619330 No abstract available.

4

Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice.

Mazurek M, Huisman MV, Lip GYH. Mazurek M, et al. Am J Med. 2017 Feb;130(2):135-145. doi: 10.1016/j.amjmed.2016.09.012. Epub 2016 Oct 13. Am J Med. 2017. PMID: 27746290 Review.

5

In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.

Mazurek M, Lip GY. Mazurek M, et al. Ann Intern Med. 2016 Oct 18;165(8):JC38. doi: 10.7326/ACPJC-2016-165-8-038. Ann Intern Med. 2016. PMID: 27750298 No abstract available.

6

CHA₂DS₂-VASc score risk factors as predictors of stroke after acute coronary syndrome: Can we really be sure there is no atrial fibrillation?

Mazurek M, Lip GY. Mazurek M, et al. Eur Heart J Acute Cardiovasc Care. 2018 Apr;7(3):275-277. doi: 10.1177/2048872616688455. Epub 2017 Jan 6. Eur Heart J Acute Cardiovasc Care. 2018. PMID: 28058849 No abstract available.

7

Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta-analysis on gender differences.

Proietti M, Cheli P, Basili S, Mazurek M, Lip GY. Proietti M, et al. Among authors: mazurek m. Pharmacol Res. 2017 Mar;117:274-282. doi: 10.1016/j.phrs.2017.01.004. Epub 2017 Jan 7. Pharmacol Res. 2017. PMID: 28082173 Review.

8

Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation.

Purmah Y, Proietti M, Laroche C, Mazurek M, Tahmatzidis D, Boriani G, Novo S, Lip GYH; EORP-AF General Pilot Registry Investigators. Purmah Y, et al. Among authors: mazurek m. Europace. 2018 Feb 1;20(2):243-252. doi: 10.1093/europace/euw421. Europace. 2018. PMID: 28160483 Free article.

9

Gastrointestinal Bleeding and Direct Oral Anticoagulants Amongst Patients With Atrial Fibrillation in the "Real World".

Mazurek M, Lip GYH. Mazurek M, et al. Gastroenterology. 2017 Apr;152(5):932-934. doi: 10.1053/j.gastro.2017.02.027. Epub 2017 Mar 1. Gastroenterology. 2017. PMID: 28259717 No abstract available.

10

Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry.

Mazurek M, Shantsila E, Lane DA, Wolff A, Proietti M, Lip GYH. Mazurek M, et al. Stroke. 2017 Aug;48(8):2198-2205. doi: 10.1161/STROKEAHA.116.016146. Epub 2017 Jul 5. Stroke. 2017. PMID: 28679859 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

558 results

Search Page

Filters